In this activity, learn about the epidemiology, etiology, diagnosis, and treatment of idiopathic pulmonary fibrosis (IPF), a deadly disease with a 5-year survival rate of only 20% to 30%. Fernando J. Martinez, MD, MS, will take you through frequently asked questions regarding IPF, including the potential for antifibrotic therapy to affect disease progression. 

Learning Objectives

  • Demonstrate an understanding of IPF prevalence, morbidity, and mortality
  • Demonstrate an understanding of the signs and symptoms of IPF and the importance of early recognition and referral
  • Differentiate the efficacy and safety data for available IPF treatments 

Faculty Disclosures

Fernando J. Martinez, MD, MS

Advisory Board for AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Concert Pharmaceuticals, Inc.; Genentech; GlaxoSmithKline; Medical Leverage; Mereo Biopharma Group; Novartis Pharmaceuticals Corporation; Pearl Therapeutics, Inc.; ProterixBio, Inc.; Theravance Biopharma; and Veracyte, Inc. Contracted Research for Afferent Pharmaceuticals; AstraZeneca; Biogen, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Gilead Sciences Medical Affairs; GlaxoSmithKline; and Veracyte, Inc. Speaker’s Bureau for AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; National Association for Continuing Education Inc.; Novartis Pharmaceuticals Corporation; PeerView, Inc.; Potomac Pharma Inc.; Prime Pharma; UpToDate, Inc.; and WebMD. 


Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

Commercial Supporter

Boehringer Ingelheim Pharmaceuticals



Education Partner

Miller Medical Communications, LLC. 

Fine Print

Internet Explorer (version 9.0 and above) is the minimum supported browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

pmiCME Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. pmiCME, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. pmiCME is the accredited provider for this activity.

Disclosures and Conflict of Interest
pmiCME requires all individuals in a position to influence educational content for pmiCME-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. pmiCME assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by pmiCME or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.